Evaluation of a TAP Block Given During Laparoscopic Colorectal Surgery to Help Control Pain (TAP Block)
|ClinicalTrials.gov Identifier: NCT01731782|
Recruitment Status : Completed
First Posted : November 22, 2012
Last Update Posted : June 8, 2015
Patients experience pain after surgery mostly from their abdominal wounds, even when those wounds are small. Decreasing that pain has many benefits. It improves comfort, decreases stress response and might improve the outcome of the surgery. Local anesthesia (which is a numbing agent given directly at the site of pain via a needle) is given to decrease the pain that is felt after surgery and decrease the need for strong pain medications which can have negative side effects.
One promising way to give local pain medication is called the "transversus abdominis plane" or TAP block. This method works by directly blocking the nerves in the abdomen that are the cause of the pain patients feel in their incision after surgery. This is done by injecting a numbing agent (Bupivacaine) into the area of their abdomen where their nerves are located that cause pain.
In the case of nerves that carry sensation, bupivacaine blocks the pain sensation traveling in a particular nerve.
Patients will be randomized (like a flip of a coin) to receive either a normal saline injection or the bupivacaine injection.
The purpose of this study will be to prove the effectiveness of local anesthetic given via a TAP block in improving postoperative pain, decreasing the use of pain medications, decreasing postoperative nausea and vomiting and improve surgical outcomes such as hospital length of stay in laparoscopic colorectal surgery.
|Condition or disease||Intervention/treatment|
|Colorectal Disease||Drug: bupivacaine Drug: normal saline placebo (for bupivacaine)|
Using standard surgical procedures, the surgeon will proceed with the planned laparoscopic surgery. All procedures will be done by straight laparoscopic technique according to standard of care. At the completion of the procedure, and under laparoscopic control, patients will have a TAP block placed by the attending surgeon. The clinical research nurse involved in the research will prep the solution to be injected and the surgeon will be blinded as to whether the patient will be receiving normal saline or Marcaine in the TAP blocks. The block will be administered between the costal margin and iliac crest in the anterior axillary line. A Braun Stimuplex A insulated needle (80 mm 21 gauge) with 0.5 mL/kg solution (max of 30 ml) is passed through the skin, and then continued until two distinct "pops" are felt, which indicates the needle piercing each of the two fascial layers. The needle is then deemed to be in the inter-muscular plane between internal oblique and transversus abdominis muscles respectively, to target the spinal nerves in this plane. The laparoscope will be visualizing for the needle tip to ensure that it does not penetrate the peritoneum or inject pre-peritoneally. The local anesthetic is infiltrated in two separate injections into the same plane on each side. If a sub-peritoneal bleb is seen to be raised by the laparoscope, then the needle will be withdrawn slightly. Two thirds of the solution is injected, and the needle is withdrawn 5 mm and the remaining solution is injected. If injecting in the correct plane, then a smooth raised area of fluid, covered by transversus will be seen via the laparoscope. This procedure is repeated on the patients other side, to complete a bilateral block. Depending on their randomization, patients will receive one of the following solutions:
Group A: Represents the control group and will receive 0.5 ml/kg of 0.9% normal saline for a maximum of 30 ml.
Group B: Represents the experimental group and will receive 0.5 ml/kg of 0.25% Marcaine (bupivacaine) for a maximum of 30 ml.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||79 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Primary Purpose:||Supportive Care|
|Official Title:||Evaluation of a TAP Block as Part of an Enhanced Recovery Pathway in Laparoscopic Colorectal Surgery: A Prospective, Randomized, Double-blinded Multi-institution Trial|
|Study Start Date :||July 2012|
|Primary Completion Date :||August 2014|
|Study Completion Date :||August 2014|
Active Comparator: bupivacaine
bupivacaine-0.5ml/kg of 25% bupivacaine for maximum of 30ml
Other Name: Marcaine
Placebo Comparator: normal saline
Normal saline placebo-0.5ml/kg of 0.9% normal saline (max of 30ml)to mimic bupivacaine
Drug: normal saline placebo (for bupivacaine)
Normal saline to mimic bupivacaine
- Evaluate the improvement of postoperative pain [ Time Frame: Daily after surgery up until discharge up to 10 days ]Daily pain scores while in the hospital
- evaluate the use of analgesics [ Time Frame: daily until 30 days after surgery ]log the daily use of analgesics (PCA and oral) in morphine equivalents and opioids used
- evaluate postoperative nausea and vomiting [ Time Frame: daily after surgery until discharge up to 10 days ]daily post-operative nausea/vomiting scores and log the daily use of antiemetics
- length of hospital stay [ Time Frame: admission until day of discharge up to 10 days ]document the length of the hospital stay by the number of days from admission until discharge
- Day of return of bowel function [ Time Frame: daily after surgery until discharge up to 10 days ]Log the day bowel function returns by day postoperative that flatus returns and has first stool
- Evaluate post operative occurence of ileus [ Time Frame: daily after surgery until discharge up to 10 days ]Measure post operative complications, including ileus (defined as reduction in diet and placement of a nasogastric tube)
- Readmission to the hospital [ Time Frame: Discharge up to 30 days after surgery ]Note and follow any readmission to the hospital after surgery for up to 30 days
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01731782
|United States, Ohio|
|University Hospitals Case Medical Center|
|Cleveland, Ohio, United States, 44106|
|Principal Investigator:||Conor P Delaney, MD.,PhD||University Hospitals Cleveland Medical Center|